Evolution of bioengineered blood vessels
Biotechnology approaches to repair and replace arteries have been under development for more than a century. Early synthetic approaches used rubber-based replacements, which then evolved into the use of polymer fabrics and, more recently, into biological approaches that permit the growth of blood vessels in the laboratory. Niklason and Lawson review the scientific and technological advances that allow the regeneration of a patient’s own blood vessels. The authors discuss how blood vessel cells, when combined with suitable substrates for tissue growth under conditions that mimic human physiology, can produce functional bioengineered arteries. These biological approaches pave the way to advancing how vascular disease is managed and treated in the future.
Science, this issue p. eaaw8682
Vascular replacement and repair for the treatment of atherosclerotic disease, infection, and traumatic injury are some of the most commonly performed surgical procedures in the Western world. In the United States alone, hundreds of thousands of coronary and peripheral arteries are repaired, replaced, or bypassed every year. But despite the enormity of the clinical need for engineered arterial replacements, the equally enormous simultaneous challenges of immune acceptance, requisite tissue mechanics, low thrombogenicity, and immediate availability have made the broad clinical application of engineered arteries quite difficult to achieve. In this regard, recent years have seen the fusion of cell biology, physiology, and engineering to now allow for the creation of human tissues that can truly function in the setting of vascular repair and replacement.
For a biological engineered artery to function successfully without requiring immunosuppression, the following objectives should be met: (i) The engineered artery should have an extracellular matrix of sufficient quality to provide suitable tensile, suture retention, and rupture strength properties. A focus on production of suitable amounts of high-quality cross-linked vascular collagens type I and III is probably necessary for any biological engineered artery to be successful. (ii) To minimize risks of inflammation, foreign-body response, and immune recognition, the vascular tissue matrix should be of human origin and without substantial synthetic material additives or artificial covalent cross-linking. (iii) If the engineered artery is cellular, even if the cells are nonviable, those cells should be autologous to prevent immune recognition, degradation, and aneurysm formation in the implanted vessels. (iv) Once implanted, the engineered arteries should have the potential to be remodeled, repopulated, and rejuvenated by the host. (v) For small-caliber or low-flow arterial bypass applications, it is likely that a suitable nonthrombogenic luminal surface is required. This surface may be either cellular or biochemical, but it should prevent blood coagulation contact activation, platelet adhesion and activation, and thrombosis in the arterial system.
Guided by the design criteria above, engineered blood vessels have been developed by several groups that have progressed to clinical trials. Recent clinical studies have demonstrated the feasibility of using human tissue–engineered blood vessels in the settings of vascular trauma, peripheral arterial disease, and vascular access for hemodialysis. Engineered arteries reaching the clinical domain have been composed of autologous cells or allogeneic cells, or have been engineered from allogeneic cells or tissues and then decellularized. Vascular functionality in patients has been demonstrated in both low-pressure environments (pediatric cardiac surgery) and high-pressure environments (peripheral arterial surgery in adults).
Autologous cell approaches have shown some promise, particularly in clinical settings of venous reconstruction and low pressure and in pediatric populations. However, scaling production of engineered arteries to tens of thousands of vessels per year, as would be needed to treat arterial atherosclerosis at large scale, presents enormous logistical challenges if autologous cell sources are used. Hence, it is likely that future successes of engineered arteries will employ allogeneic human cells or cell banks to generate tissues at clinically relevant scales, and suitable strategies will be required to prevent adaptive immunity and rejection of these vessels. Furthermore, next-generation techniques such as three-dimensional bioprinting of both cells and matrix may one day allow vessel production at accelerated speeds, possibly producing usable tissues in hours or days, rather than weeks or months. Microvascular and cardiac tissue engineering are also making important strides, pointing toward a future that could enable revascularization of solid organs. The evolution of scientific thinking and approaches that have brought us to this point is summarized in this review.
Immunostaining for smooth muscle (red), progenitor cells (green), and cell nuclei (blue) shows extensive cellular repopulation of the engineered vessel. Engineered cells were implanted into the patient for 4 years. The layer of red-staining cells at the bottom of the image shows the repopulated engineered vessel wall. Blue staining at the top shows the nuclei of skin cells.
Since the advent of the vascular anastomosis by Alexis Carrel in the early 20th century, the repair and replacement of blood vessels have been key to treating acute injuries, as well as chronic atherosclerotic disease. Arteries serve diverse mechanical and biological functions, such as conducting blood to tissues, interacting with the coagulation system, and modulating resistance to blood flow. Early approaches for arterial replacement used artificial materials, which were supplanted by polymer fabrics in recent decades. With recent advances in the engineering of connective tissues, including arteries, we are on the cusp of seeing engineered human arteries become mainstays of surgical therapy for vascular disease. Progress in our understanding of physiology, cell biology, and biomanufacturing over the past several decades has made these advances possible.
This 14-Year-Old’s Discovery Could Lead to a Cure for COVID-19
With no clear end in sight to the pandemic, there is an urgent need for a cure to COVID-19. As scientists around the world work to develop possible vaccines, one 14-year-old girl from Texas has made a new discovery that could lead to a potential treatment.
On Wednesday, Anika Chebrolu from Frisco, Texas was named the winner of the 3M Young Scientist Challenge after discovering a molecule that can selectively bind to the spike protein of the SARS-COV-2 virus, which causes COVID-19.
The competition opened in December 2019 and invited students in grades five to eight to find a unique solution to an everyday problem. Anika won $25,000, a special destination trip, and the title of “America’s Top Young Scientist” for her achievement.
Her discovery could lead to important developments in COVID-19 research. By binding to the spike protein in the coronavirus, the molecule she found can potentially prevent virus entry into the host cell, and can be used in creating a potential drug to cure COVID-19.
Anika used in-silico methodology — methods and experiments that make use of computers — to screen millions of small molecules. She originally planned for her project to focus on the influenza virus, but pivoted once COVID-19 hit and she realized the severity of the pandemic. Anika was in eighth grade when she submitted the project.
She told CNN that she hopes to work with other scientists and researchers to develop her discovery into an actual cure for the virus.
At the moment, the World Health Organization (WHO) is tracking over 170 candidate vaccines around the world. However, since many of them are still in early development, the effectiveness of these vaccines are still unknown. Vaccines go through multiple stages of testing and experts predict that a vaccine will only be available to the public in 2021, at the earliest.
In August, Russia was the first country to claim to have developed a vaccine for COVID-19. However, many were skeptical as President Vladimir Putin had ordered to speed up clinical trials. The vaccine, which was not subject to the extensive Phase III testing, was registered after less than two months of human testing. Experts have said that the vaccine is based on a common cold virus, which many people have been exposed to, potentially limiting its effectiveness. Other countries working on vaccines include the United Kingdom, Germany, and China.
At the moment, there are no specific vaccines or drugs for COVID-19. Developing one to prevent or cure infection from the novel coronavirus could help decrease the number of fatalities and help hospitals manage patients better.
As of posting, there have been a total of over 40 million cases of COVID-19 and 1.1 million deaths around the world. The United States and India have the most number of cases, with 8.1 million and 7.5 million total COVID-19 cases respectively. Few places across the globe have successfully managed the virus, including New Zealand, Taiwan, and Singapore.
Mammalian lipid droplets are innate immune hubs integrating cell metabolism and host defense
Cells drop a bomb on pathogens
Lipid droplets (LDs) accumulate in cells to serve as lipid storage organelles. They are also an attractive source of nutrients for many pathogens. Bosch et al. show that various proteins involved in innate immunity form complexes on LDs in response to bacterial lipopolysaccharide (see the Perspective by Green). Upon activation, LDs became physically uncoupled from mitochondria, driving a shift in cells from oxidative phosphorylation to aerobic glycolysis. This work highlights the ability of LDs both to kill pathogens directly and to establish a metabolic environment conducive to host defense. This may inform future antimicrobial strategies in the age of antibiotic resistance.
In all eukaryotic cells, lipid droplets (LDs) store and supply essential lipids to produce signaling molecules, membrane building blocks, and metabolic energy. The LD monolayer also accommodates proteins not obviously related to lipids, such as transcription factors, chromatin components, and toxic proteins.
Common parasites (such as trypanosomes and Plasmodium falciparum), bacteria (such as mycobacteria and Chlamydia), and viruses (such as hepatitis C and dengue) induce and target LDs during their life cycles. The current view is that LDs support infection, providing microorganisms with substrates for effective growth.
Successful innate defense is critical for survival, and host species have efficiently coevolved with pathogens to develop a plethora of immune responses. Multiple cues, including cellular stress and danger-associated molecular patterns such as lipopolysaccharide (LPS), induce LD formation. Thus, LD localization and dynamics may potentially be advantageous for organizing an intracellular host defense. We have investigated the possibility that mammalian LDs have a direct and regulated role in innate immunity.
We show that mammalian LDs are endowed with a protein-mediated antimicrobial capacity, which is up-regulated during polymicrobial sepsis and by LPS. Light and electron microscopy demonstrated specific association of LDs and bacteria in human macrophages, suggesting the existence of docking mechanisms that facilitate the engagement of antibacterial LD proteins with bacteria.
A comparative mass spectrometry profiling of proteins differentially associated with LDs in response to LPS (LPS-LDs) revealed the profound remodeling of the organelle proteome. A stringent evaluation identified 689 proteins differentially regulated on LPS-LDs (317 enriched and 372 reduced). Ingenuity Pathway Analysis revealed an enrichment of innate immune system–related components and reduction of metabolism-related LD-resident proteins. Additional analyses suggested that LDs serve as innate immune hubs, integrating major intra- and extracellular immune responses.
Among the five members of the perilipin family of LD surface proteins (PLINs), PLIN5 was the only one down-regulated on LPS-LDs. PLIN5 reduction promoted physical and functional disconnection of LPS-LDs and mitochondria, with a concomitant reduction of oxidative metabolism and ketogenesis. Forced PLIN5 reexpression increased the number of LD-mitochondria contacts, reducing LD-bacteria interactions and compromising the antimicrobial capacity of cells.
By contrast, PLIN2 was the most up-regulated PLIN on LPS-LDs. Gene interaction analysis revealed that multiple immune proteins nucleated around PLIN2 in response to LPS. LPS-LDs accrued several interferon-inducible proteins such as viperin, IGTP, IIGP1, TGTP1, and IFI47. Furthermore, LPS-LDs also accumulated cathelicidin (CAMP), a broad-spectrum antimicrobial peptide with chemotactic properties. Cells overexpressing a LD-associated CAMP were more resistant to different bacterial species, including Escherichia coli, methicillin-resistant Staphylococcus aureus, and Listeria monocytogenes.
These results demonstrate that LDs form a first-line intracellular defense. They act as a molecular switch in innate immunity, responding to danger signals by both reprogramming cell metabolism and eliciting protein-mediated antimicrobial mechanisms. Mechanisms of LD trafficking and docking with phagocytic and parasitophorous membranes, observed here and described for several pathogens, may facilitate the delivery of immune proteins located on the LD surface. Intracellular LDs can provide infected cells with several biological benefits, serving as a location to attract pathogens as well as coordinating different immune systems that operate simultaneously against different classes of pathogens. LDs may also sequester cytotoxic compounds (such as antimicrobial peptides), reducing damage to other cellular organelles. In view of the widespread resistance to current antibiotics, this study helps decipher molecular mechanisms involved in antimicrobial defense that could be exploited for development of new anti-infective agents.
Serial blockface scanning electron microscopy data reconstruction showing an infected macrophage. Bacteria (blue) and LDs (green) in the three-dimensional dataset have been colored and projected onto a single image. LDs associate with the bacteria surface (black square). This interaction is proposed to bring a specific set of antipathogenic proteins in contact with the membrane-enclosing bacteria (inset).
Lipid droplets (LDs) are the major lipid storage organelles of eukaryotic cells and a source of nutrients for intracellular pathogens. We demonstrate that mammalian LDs are endowed with a protein-mediated antimicrobial capacity, which is up-regulated by danger signals. In response to lipopolysaccharide (LPS), multiple host defense proteins, including interferon-inducible guanosine triphosphatases and the antimicrobial cathelicidin, assemble into complex clusters on LDs. LPS additionally promotes the physical and functional uncoupling of LDs from mitochondria, reducing fatty acid metabolism while increasing LD-bacterial contacts. Thus, LDs actively participate in mammalian innate immunity at two levels: They are both cell-autonomous organelles that organize and use immune proteins to kill intracellular pathogens as well as central players in the local and systemic metabolic adaptation to infection.
The nucleus acts as a ruler tailoring cell responses to spatial constraints
The nucleus makes the rules
Single cells continuously experience and react to mechanical challenges in three-dimensional tissues. Spatial constraints in dense tissues, physical activity, and injury all impose changes in cell shape. How cells can measure shape deformations to ensure correct tissue development and homeostasis remains largely unknown (see the Perspective by Shen and Niethammer). Working independently, Venturini et al. and Lomakin et al. now show that the nucleus can act as an intracellular ruler to measure cellular shape variations. The nuclear envelope provides a gauge of cell deformation and activates a mechanotransduction pathway that controls actomyosin contractility and migration plasticity. The cell nucleus thereby allows cells to adapt their behavior to the local tissue microenvironment.
The human body is a crowded place. This crowding is even more acute when the regulation of cell growth and proliferation fails during the formation of a tumor. Dealing with the lack of space in crowded environments presents cells with a challenge. This is especially true for immune cells, whose task is to patrol tissues, causing them to experience both acute and sustained deformation as they move. Although changes in tissue crowding and associated cell shape alterations have been known by pathologists to be key diagnostic traits of late-stage tumors since the 19th century, the impact of these changes on the biology of cancer and immune cells remains unclear. Moreover, it is not known whether cells can detect and adaptively respond to deformations in densely packed spaces.
To test the hypothesis that cells possess an ability to detect and respond to environmentally induced changes in their shape, we fabricated artificial microenvironments that mimic the conditions experienced by tumor and immune cells in a crowded tissue. By combining dynamic confinement, force measurements, and live cell imaging, we were able to quantify cell responses to precisely controlled physical perturbations of their shape.
Our results show that, although cells are surprisingly resistant to compressive forces, they monitor their own shape and develop an active contractile response when deformed below a specific height. Notably, we find that this is achieved by cells monitoring the deformation of their largest internal compartment: the nucleus. We establish that the nucleus provides cells with a precise measure of the extent of their deformation. Once cell compression exceeds the size of the nucleus, it causes the bounding nuclear envelope (NE) to unfold and stretch. The onset of the contractile response occurs when the NE reaches a fully unfolded state. This transition in the mechanical state of the NE and its membranes permits calcium release from internal membrane stores and activates the calcium-dependent phospholipase cPLA2, an enzyme known to operate as a molecular sensor of nuclear membrane tension and a critical regulator of signaling and metabolism. Activated cPLA2 catalyzes the formation of arachidonic acid, an omega-6 fatty acid that, among other processes, potentiates the adenosine triphosphatase activity of myosin II. This induces contractility of the actomyosin cortex, which produces pushing forces to resist physical compression and to rapidly squeeze the cell out of its compressive microenvironment in an “evasion reflex” mechanism.
Although the nucleus has traditionally been considered a passive storehouse for genetic material, our work identifies it as an active compartment that rapidly convers mechanical inputs into signaling outputs, with a critical role of its envelope in this sensing function. The nucleus is able to detect environmentally imposed compression and respond to it by generating a signal that is used to change cell behaviors. This phenomenon plays a critical role in ensuring that cells, such as the immune cells within a tumor, can adapt, survive, and efficiently move through a crowded and mechanically heterogeneous microenvironment. Characterizing the full spectrum of signals triggered by nuclear compression has the potential to elucidate mechanisms underlying signaling, epigenetic, and metabolic adaptations of cells to their mechanoenvironment and is thus an exciting avenue for future research.
(1) Cell confinement below resting nucleus size, leading to nuclear deformation and to unfolding, and stretching of the nuclear envelope. (2) Nuclear membrane tension increase, which triggers calcium release, cPLA2 activation, and arachidonic acid (ARA) production. (3) Actomyosin force (F) generation. (4) Increased cell migratory capacity and escape from confinement.
The microscopic environment inside a metazoan organism is highly crowded. Whether individual cells can tailor their behavior to the limited space remains unclear. In this study, we found that cells measure the degree of spatial confinement by using their largest and stiffest organelle, the nucleus. Cell confinement below a resting nucleus size deforms the nucleus, which expands and stretches its envelope. This activates signaling to the actomyosin cortex via nuclear envelope stretch-sensitive proteins, up-regulating cell contractility. We established that the tailored contractile response constitutes a nuclear ruler–based signaling pathway involved in migratory cell behaviors. Cells rely on the nuclear ruler to modulate the motive force that enables their passage through restrictive pores in complex three-dimensional environments, a process relevant to cancer cell invasion, immune responses, and embryonic development.
More than 220,000 people have died from Covid-19 in the US
CVS Health will hire 15,000 more workers ahead of flu season.
Airports screened more than one million travelers for the first time since mid-March.
Check out some wonderful Playdate game demos, including a low-fi Doom
Puerto Rican Piñon
Still no first stimulus check? How to track it and report your absent payment to the IRS – CNET
Tech2 months ago
Check out some wonderful Playdate game demos, including a low-fi Doom
Food2 weeks ago
Puerto Rican Piñon
Tech2 months ago
Still no first stimulus check? How to track it and report your absent payment to the IRS – CNET
Science2 months ago
Elon Musk promises demo of a working Neuralink device on Friday
Tech4 weeks ago
Fitbit Sense review: enough bugs to raise your heart rate
Tech3 months ago
Spotify Duo vs. Family vs. Individual: Which Premium Spotify plan is best? – CNET
Entertainment1 month ago
Kim Kardashian Appears To Give Birth To Kylie Jenner In Leaked Kanye West & Tyga Video — Watch
Entertainment3 months ago
Jake Paul’s LA Mansion Raided By FBI During Mysterious Early Morning Search – Watch